X4 Pharmaceuticals, Inc. (XFOR)
NASDAQ: XFOR · Real-Time Price · USD
4.040
-0.270 (-6.26%)
At close: Mar 27, 2026, 4:00 PM EDT
4.000
-0.040 (-0.99%)
After-hours: Mar 27, 2026, 4:37 PM EDT
X4 Pharmaceuticals Employees
X4 Pharmaceuticals had 45 employees as of December 31, 2025. The number of employees decreased by 98 or -68.53% compared to the previous year.
Employees
45
Change (1Y)
-98
Growth (1Y)
-68.53%
Revenue / Employee
$780,289
Profits / Employee
-$1,759,978
Market Cap
367.32M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 45 | -98 | -68.53% |
| Dec 31, 2024 | 143 | 50 | 53.76% |
| Dec 31, 2023 | 93 | 23 | 32.86% |
| Dec 31, 2022 | 70 | -13 | -15.66% |
| Dec 31, 2021 | 83 | 11 | 15.28% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
Employee RankingsXFOR News
- 12 days ago - X4 Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 25 days ago - X4 Pharmaceuticals to Participate in a Fireside Chat at the Leerink Global Healthcare Conference - GlobeNewsWire
- 26 days ago - X4 Pharmaceuticals: An Undercovered Biotech Trade With A Funded Path To FDA Approval - Seeking Alpha
- 26 days ago - X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 4 weeks ago - X4 Pharmaceuticals Receives Positive Opinion from the EMA CHMP Recommending Approval of Mavorixafor in the EU for WHIM Syndrome - GlobeNewsWire
- 5 weeks ago - X4 Pharmaceuticals, Inc. (XFOR) Presents at Guggenheim Securities Emerging Outlook: Biotech Summit 2026 Transcript - Seeking Alpha
- 7 weeks ago - X4 Pharmaceuticals to Participate in Guggenheim's Emerging Outlook: Biotech Summit 2026 - GlobeNewsWire
- 4 months ago - X4 Pharmaceuticals: Betting On Mavorixafor For Chronic Neutropenia - Seeking Alpha